الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 353 |  |  |
| | | from | 353 | | |
Abstract
Chapter I (Introduction):
An introductory part describing the chemistry of thienopyrimidine, different approaches for its synthesis and c-Kit/PDGFR-α dual inhibitors as targeted chemotherapeutic agents such as imatinib, telatinib, tivozanib and amuvatinib.
Chapter II (Research Objectives):
The aim of this research is to synthesize novel c-Kit/PDGFR-α dual inhibitors as structural analogues of amuvatinib and evaluate their cytotoxic effect on pancreatic cancer cell line (PANC-1). Our strategy is directed toward the design of a variety of ligands by replacing benzofuro[3,2-d]pyrimidine of amuvatinib with thieno[2,3-d]pyrimidine derivatives in the hope of discovering more active ATP site inhibitors.
Chapter III (Theoretical Discussion):
Synthetic pathways that have been followed to obtain final new compounds and their mechanisms, spectral data, biological results and molecular modeling.
Chapter IV (Experimental):
A number of new thieno[2,3-d]pyrimidine derivatives were synthesized. The potential cytotoxicity of the synthesized compounds was tested on PANC-1 using Skehan methodology. Docking study for the most active derivatives was carried out on the crystal structure of both PDGFR-α and c-Kit.
Chapter V (Conclusion):
A summary of the present study and conclusions.
Chapter VI (References):
A list of references which were used and their arrangement according to their order in the thesis.